Generics Makers Urge Speedier Approvals to Ensure First-Filer Exclusivity

The FDA should speed up its ANDA median approval times so that generics manufacturers with first-filer status don’t lose their 180 days of marketing exclusivity, firms said.
Drug Industry Daily